ارزیابی حین عمل غده لنفاوی نگهبان برای بیماران مبتلا به سرطان پستان T1-N0 : همیشه یا هرگز ؟ تجزیه و تحلیل ریسک / سود و سود / زیان
|کد مقاله||سال انتشار||مقاله انگلیسی||ترجمه فارسی||تعداد کلمات|
|6710||2010||8 صفحه PDF||سفارش دهید||محاسبه نشده|
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : European Journal of Surgical Oncology (EJSO), Volume 36, Issue 8, August 2010, Pages 737–744
Aim To investigate whether omitting intra-operative staging of the sentinel lymph node (SLN) in T1-N0 breast-cancer patients is feasible and convenient because it could allow a more efficient management of human and logistic resources without leading to an unacceptable increase in the rate of delayed axillary lymph node dissection (ALND). Methods According to the experimental procedure, T1a–T1b-patients were to not receive any intra-operative SLN evaluation on frozen sections (FS). In all T1c-patients, the SLN was macroscopically examined; if the node appeared clearly free of disease, no further intra-operative assessment was performed; if the node was clearly metastatic or presented a dubious aspect, the pathologist proceeded with analysis on FS. T2-patients, enrolled in the study as reference group, were treated according to the institutional standard procedure; they all received SLN staging on FS. Results The study included 395 T1-N0-patients. Among the 118 T1a–T1b-patients whose SLN was not analyzed at surgery, 12 (10.2%) were recalled for ALND. In the group of 258 T1c-patients, 112 received SLN analysis on FS and 146 did not. An SLN falsely negative either at macroscopic or FS examination was found in 33 (12.8%) cases. Overall, the rate of recall for ALND was 11.6% as compared to 8.4% in T2-patients. Using the experimental protocol, the institution reached a 9.6% cost saving, as compared to the standard procedure. Conclusions Omission of SLN intra-operative staging in T1-N0-patients is rather safe. It provides the institution with both management and economical advantages.
Resection of the primary tumor together with axillary lymph node dissection (ALND) has long been the standard surgical management of early-stage breast-cancer. However, axillary metastases are found in only ∼40% of the cases;1 and 2 the remaining patients derive no benefit from axillary surgery but unnecessarily face common morbidities from ALND.3 For patients with early-stage tumor (T1–T2) and clinically negative lymph nodes (N0), this problem is now obviated by the use of the sentinel lymph node biopsy (SLNB). This minimally invasive, safe and acceptably accurate procedure has a high negative predictive value for axillary status4, 5 and 6 and is nowadays the recommended method for axilla staging.7, 8 and 9 Nevertheless, several aspects need further evaluation: 1) is ALND mandatory for all patients with metastatic SLN?; 2) what is the prognostic significance of SLN micrometastases, particularly those evidenced only by immunohistochemistry, and of isolated tumor cells? 3) can patients presenting both SLN micrometastasis and small-size tumor be spared ALND? 4) is it necessary to always perform SLNB and, when needed, ALND during the initial surgery or could these procedures be postponed in specific instances? This last question emerges from several considerations8, 10 and 11: screening mammography has increased the proportion of patients presenting a ≤1 cm tumor; these patients have a low probability of nodal disease as the incidence of positive SLN increases with tumor size; the presence of SLN micrometastases is predominantly associated with pT1a–1b tumors; intra-operative false-negative SLN staging on frozen sections (FS) is largely due to the failure to detect micrometastasis by hematoxylin–eosin; pT1c–pT2-patients mostly benefit from FS examination since the sensitivity of the procedure increases with tumor size.
نتیجه گیری انگلیسی
The experimental protocol here evaluated (no SLN evaluation or macroscopic examination) seems to be rather safe for the subgroup of T1-N0-patients. Furthermore, it is beneficial for the institution, in terms of efficiency and costs. Alternatively, the possibility not to perform any intra-operative evaluation but to always defer SLN assessment to post-surgery definitive diagnosis might be considered for all T1-N0-patients. A third option is to let the patients, fully informed on the risks and implications of the procedure, freely choose whether to undergo intra-operative SLN evaluation and, if needed, immediate ALND. Intra-operative SLN examination should remain the standard procedure for all T2-N0-patients.